Compare Axogen Inc (AXGN) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs iShares China Large-Cap ETF — how do they compare? Axogen Inc trades at $49.19 (market cap $2.61B), while iShares China Large-Cap ETF trades at $35.22. The key difference: Axogen Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| AXGN | FXI | |
|---|---|---|
Market Cap | $2.61B | — |
Sector | Technology | — |
52-Week High | $48.48 | $41.75 |
52-Week Low | $14.16 | $31.59 |
Enterprise Value | $2.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $48.53, up 0.64% today, with a bullish technical signal from moving averages and strong analyst support. Q2 2026 revenue grew 23.1% to $69.7M, beating estimates, and full-year guidance was raised to at least $279M. However, the company remains unprofitable with a net income margin of -13.36% and negative ROE, reflecting high SG&A costs relative to revenue.
The outlook is mixed: robust revenue growth and FDA-backed nerve care platform expansion offer upside, but persistent losses and high valuation multiples (P/S 9.57) pose risks. With 84% analyst buy ratings and a $54.33 price target, near-term momentum depends on execution toward profitability amid competitive and reimbursement pressures.
FXI, the iShares China Large-Cap ETF, trades at $35.26, down 3.37% on the day, reflecting recent pressure on Chinese equities. Technical indicators show a bullish moving average signal but neutral oscillators, with key resistance at $37. Recent news highlights China's export strength and state-backed economic support, though geopolitical tensions and U.S. restrictions pose headwinds. The ETF offers exposure to China's financial and industrial giants, with a dividend scheduled for June 2026.
The outlook for FXI is mixed; bullish technical trends and China's policy support may drive gains, but risks include U.S.-China tensions and domestic economic volatility. Investors should weigh diversification benefits against regulatory and macroeconomic uncertainties, with Wall Street sentiment cautious amid fluctuating analyst views.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
